| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Boyalife Investment Fund I, Inc. last filed a Form 4 in September 2017, as 10% Owner at AURX.
At the last filing, the largest reported position was 4,900,000 shares of AURX. Net of sales, the AURX filings show accumulation of 3,150,000 shares.
Boyalife Investment Fund I, Inc. has 1 Form 4 filing on record in September 2017, as 10% Owner at Nuo Therapeutics (AURX), 2017.
The 1 reported transaction was 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $700K and no sales.
The only open-market purchase was 3,150,000 shares of AURX at an average $0.22 on September 11, 2017, about $700K.
Shares as reported in the last Form 4 for each company; the most recent is from September 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2017 | AURX Nuo Therapeutics, Inc. | 10% Owner | Buy | 3,150,000 | $0.22 | $699,930.00 | +180.0% |